378 related articles for article (PubMed ID: 18077994)
21. A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
[TBL] [Abstract][Full Text] [Related]
22. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Berenson JR; Jagannath S; Barlogie B; Siegel DT; Alexanian R; Richardson PG; Irwin D; Alsina M; Rajkumar SV; Srkalovic G; Singhal S; Limentani S; Niesvizky R; Esseltine DL; Trehu E; Schenkein DP; Anderson K
Cancer; 2005 Nov; 104(10):2141-8. PubMed ID: 16206291
[TBL] [Abstract][Full Text] [Related]
23. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
Berenson JR; Yellin O; Kazamel T; Hilger JD; Chen CS; Cartmell A; Woliver T; Flam M; Bravin E; Nassir Y; Vescio R; Swift RA
Leukemia; 2012 Jul; 26(7):1675-80. PubMed ID: 22354206
[TBL] [Abstract][Full Text] [Related]
24. A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
Lee KW; Yun T; Song EK; Na II; Shin H; Bang SM; Lee JH; Lee ST; Kim JH; Yoon SS; Lee JS; Park S; Kim BK; Kim NK
J Korean Med Sci; 2005 Aug; 20(4):598-62. PubMed ID: 16100450
[TBL] [Abstract][Full Text] [Related]
25. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC
J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544
[TBL] [Abstract][Full Text] [Related]
26. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin DH; Rajkumar SV; Srkalovic G; Alsina M; Anderson KC
Cancer; 2006 Mar; 106(6):1316-9. PubMed ID: 16470606
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; San Miguel JF; Cavenagh JD; Anderson KC
Br J Haematol; 2007 Jun; 137(5):429-35. PubMed ID: 17451408
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
Pantani L; Zamagni E; Zannetti BA; Pezzi A; Tacchetti P; Brioli A; Mancuso K; Perrone G; Rocchi S; Tosi P; Cavo M
Ann Hematol; 2014 Jan; 93(1):123-8. PubMed ID: 23864035
[TBL] [Abstract][Full Text] [Related]
29. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
[TBL] [Abstract][Full Text] [Related]
30. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
Fukushima T; Nakamura T; Iwao H; Nakajima A; Miki M; Sato T; Sakai T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Nakajima H; Motoo Y; Umehara H
Anticancer Res; 2011 Jun; 31(6):2297-302. PubMed ID: 21737655
[TBL] [Abstract][Full Text] [Related]
32. [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].
Titos-Arcos JC; León-Villar J; de Arriba de la Fuente F; Moreno Belmonte MJ; Iranzo Fernández MD
Farm Hosp; 2012; 36(4):275-81. PubMed ID: 22115856
[TBL] [Abstract][Full Text] [Related]
33. Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P
Oncology; 2006; 70(6):474-82. PubMed ID: 17283449
[TBL] [Abstract][Full Text] [Related]
34. A practical update on the use of bortezomib in the management of multiple myeloma.
San Miguel J; Bladé J; Boccadoro M; Cavenagh J; Glasmacher A; Jagannath S; Lonial S; Orlowski RZ; Sonneveld P; Ludwig H
Oncologist; 2006 Jan; 11(1):51-61. PubMed ID: 16401713
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J
Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191
[TBL] [Abstract][Full Text] [Related]
36. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
[TBL] [Abstract][Full Text] [Related]
37. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
[TBL] [Abstract][Full Text] [Related]
38. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
Fisher RI; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S; Stadtmauer EA; O'Connor OA; Shi H; Boral AL; Goy A
J Clin Oncol; 2006 Oct; 24(30):4867-74. PubMed ID: 17001068
[TBL] [Abstract][Full Text] [Related]
39. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
[TBL] [Abstract][Full Text] [Related]
40. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
Richardson PG; Wolf J; Jakubowiak A; Zonder J; Lonial S; Irwin D; Densmore J; Krishnan A; Raje N; Bar M; Martin T; Schlossman R; Ghobrial IM; Munshi N; Laubach J; Allerton J; Hideshima T; Colson K; Poradosu E; Gardner L; Sportelli P; Anderson KC
J Clin Oncol; 2011 Nov; 29(32):4243-9. PubMed ID: 21990396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]